WEEKS 1-4
Building the habit
Low starting dose. Establishing the morning routine. Most people don't notice dramatic changes yet.
All content on this page has been medically reviewed by: Hassan Thwaini, Clinical Pharmacist and Copywriter, Master of Pharmacy (MPharm) on 6 May, 2026. GPhC Registration: 2221320View profile
A new version of a familiar treatment
Wegovy tablets are an oral version of semaglutide - the same medicine as the Wegovy injection, just taken differently. Instead of a weekly injection, it's a daily tablet absorbed through your digestive system.
The mechanism is the same: it mimics a natural hormone that reduces appetite and helps regulate blood sugar, taken alongside a healthy diet and exercise.1
What does it mean if I pre-order the Wegovy Pill?
To pre-order the Wegovy Pill, you'll need to complete a consultation. This should only take a couple of minutes. Your health profile will then be reviewed by a clinician and if clinically appropriate, you'll receive your medication as soon as it's available at the beginning of July.
How effective are Wegovy tablets?
In a 64-week clinical trial, participants taking oral semaglutide 25mg alongside lifestyle support lost an average of 16.6% of their body weight, versus 2.2% with placebo.1
Based on the OASIS 4 Phase 3 trial, conducted alongside lifestyle intervention. Results represent estimated outcomes assuming 100% adherence in a clinical trial population. As with all weight loss treatments, individual results varied.
| Weight loss achieved | Semaglutide tablets¹ (25mg) | Placebo |
|---|---|---|
| ≥5% body weight loss | 76% | 31% |
| ≥10% body weight loss | 60% | 14% |
| ≥15% body weight loss | 47% | 6% |
| ≥20% body weight loss | 28% | 3% |
The Wegovy Pill and other weight loss medications
Although the Wegovy Pill and injection contain the same active ingredient, clinical data suggests the pill produces greater average weight loss in obesity trials than the 2.4mg injectable dose.1-3
*Results are based on separate clinical trials and cannot be directly compared.
| Treatment | Study duration | Average weight loss |
|---|---|---|
| Semaglutide tablet (25mg daily)¹ | 64 weeks | 16.6% |
| Semaglutide injection (2.4mg weekly)² | 68 weeks | 14.9% |
| Tirzepatide injection (15mg weekly)³ | 72 weeks | 20.9% |
Can you get the Wegovy Pill in the UK?
The Wegovy Pill has received MHRA approval in the UK. Pre-order now and if clinically approved, you'll receive your medication when stock arrives in early July. Or join the waitlist and we'll keep you posted.
By submitting your email, you accept our privacy policy. You'll also receive exclusive updates on oral GLP-1 medications, including access opportunities through Numan.
What to expect
The journey, in four steps
Oral GLP-1s builds over time. Here's how:
WEEKS 5-8
Appetite shifts
Appetite starts to reduce. Smaller portions feel satisfying. Dose typically increases during this phase.
WEEKS 8-16
Consistent progress
Most patients see steady, measurable weight loss. Titration continues toward maintenance dose.
WEEKS 16+
Full effect
At maintenance dose, weight loss continues. Most trials show full effect after a few months.
How Numan is preparing for the Wegovy Pill
The Wegovy Pill has been approved by the MHRA. You can now join the waitlist or pre-order your treatment through Numan. If clinically approved, you'll be sent your treatment when it becomes available in early July.
In the meantime, Numan provides access to licensed, MHRA-approved weight loss treatments alongside structured clinical supervision, regular monitoring, and behavioural support.
FAQs
Your questions answered
KNOWLEDGE
Learn more about our weight loss treatments
References
Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077–87.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
Medically reviewed: